In CC, the overexpression of programmed death ligand 1 (PD-L1) is particularly rampant, affecting 55%–85% of squamous cell carcinomas and 64% of adenocarcinomas, underscoring its relevance as a therapeutic focal point [37]. This evidence concerns the gene CD274 and squamous cell carcinoma.